Figure 4.Effect of uPA treatment on migratory and invasive capabilities in human MTA2-depleted osteosarcoma cells. Treatment with or without Rh-uPA (200 ng/mL) in shLuc and shMTA2 osteosarcoma cells for 24 h, followed by the assessment of cell migration and invasion ability using the in vitro Boyden chamber migration and invasion assay. ** P < 0.01, compared with shLuc cells; # P < 0.05, compared with shMTA2 cells.
